Overview

A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and activity of increasing doses of ICM-203 injected into the knee of subjects with mild to moderate knee osteoarthritis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ICM Biotech Australia Pty Ltd.